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Abstract
Enteroviruses (EVs) constitute the most common cause of aseptic meningitis in both children and adults. Molecular techniques have
now been recognized as the reference standard for the diagnosis of EV infections, and the rapidity of the molecular diagnosis of EV
meningitis has been shown to be a determining factor in the management of patients. The rapid documentation of EV RNA in cerebro-
spinal ﬂuid (CSF) is key to adapting patient management and the therapeutic regimen. To shorten the time needed for virological docu-
mentation, we implemented EV RNA detection in two point-of-care (POC) laboratories. Here, we present the results of the POC
detection of EV RNA with the Xpert EV kit on the GeneXpert integrated system, and a comparison with the real-time RT-PCR
(rtRT-PCR) assay routinely used in the core virology laboratory. From January to September 2009, a total of 310 CSF samples were
tested. The rtRT-PCR gave 81 positive, 225 negative and four ‘indeterminate’ results. POC results were concordant in 81.6% (253/310).
Most of the discrepancies consisted of ‘indeterminate’ results at the POC level (16%). Calculated performances (excluding the indeter-
minate results) of the Xpert EV kit on the GeneXpert system in POC settings were 100%, 98.9%, 97.6% and 100% for Sensibility, Speci-
ﬁcity, positive predictive value and negative predictive value, respectively. Taken together, these results indicate that the implementation
of POC detection of EV RNA can provide robust results in <4 h, and may have a signiﬁcant impact on patient management, therapeutic
attitude, and hospitalization costs.
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Introduction
Human enteroviruses (EVs) are small, single-stranded, positive
RNA viruses. EVs constitute the most common cause of asep-
tic meningitis in both children and adults [1,2]. The rapid docu-
mentation of EV RNA in cerebrospinal ﬂuid (CSF) is key to
adapting patient management and the therapeutic regimen.
Molecular techniques have now been recognized as the
reference standard for the diagnosis of EV infections, and the
rapidity of the molecular diagnosis of EV meningitis has been
shown to be a determining factor in the management of
patients [3]. To shorten the time needed for virological
documentation, we implemented EV RNA detection in two
point-of-care (POC) laboratories connected with the unique
core virology laboratory that processes samples for inpatient
and outpatients of the public hospital system of Marseille, an
850 000-inhabitant city in south-eastern France. Up to 2008,
we performed EV RNA detection by using a home-made real-
time RT-PCR (rtRT-PCR) adapted from Watkins-Riedel to the
Taqman format [4,5]. Here, we present the results of the
POC detection of EV RNA with the Xpert EV kit on the Gen-
eXpert integrated system (both from Cepheid, Marseille
France), and a comparison with the rtRT-PCR assay that has
been routinely used in the core virology laboratory since 2004.
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Following national regulations concerning biomedical
research, the signature given at the hospital entrance ofﬁce
means that that all samples taken during hospitalization for
diagnostic purposes are accessible for research (excluding
human genetic research) without speciﬁc consent of the
patient, so ethics approval was not asked for with regard to
the terms of the Huriet-Se´rusclat law (881138). During a
9-month period (January–September 2009), the CSF samples
collected from patients admitted to three paediatric emer-
gency wards and two adult emergency wards were tested
prospectively with: (i) the Xpert EV kit on the GeneXpert
system in two POC laboratories; and (ii) a daily, routine
rtRT-PCR assay using the TaqMan technology. All CSFs were
collected from patients with suspicion of meningitis.
Sample handling
After spinal tap, the CSF sample was immediately sent to the
in situ POC laboratory, where a 140-lL volume was pro-
cessed immediately with the Xpert EV kit on the GeneXpert
system. This test was performed on all CSFs, not only on
those containing white cells. After validation within 4 h, the
result was phoned to the physician on duty and recorded in
the computer database system. The remainder of the sample
was then transferred to the core virology laboratory. where
it was included in the next daily series of EV RNA detection
with the real-time PCR methodology described hereunder.
EV RNA detection in POC laboratories
The GeneXpert system is a closed, unit dose, molecular,
microﬂuidic instrument that automatically performs virus
RNA extraction and rtRT-PCR. The system relies on sin-
gle-use cartridges including all reagents required for sample
extraction and the RT-PCR reaction. EV RNA was
detected in CSF with the Xpert EV kit on the GeneXpert
system (Cepheid France), according to the manufacturer’s
recommendations for sample processing and interpretation
of the results [6]. The presence of an internal control
allowed monitoring of the test, and failure during the qual-
ity control procedure produced an ‘indeterminate’ category
of result.
Real-time RT-PCR assay in the core virology laboratory
Virus RNA extraction was performed from 200 lL of CSF
into a 90-lL elution volume with the BioRobot EZ1 Work-
station and the EZ1 Virus Mini Kit v2.0 (both from Qiagen,
Courtaboeuf, France).
Reverse transcription was performed with the Taqman
Reverse Transcription reagents kit (Applied Biosystems,
Branchburg, NJ, USA) with 10 lL of virus RNA, 11 lL of
MgCl2, 5 lL of buffer 10X, 10 lL of dNTP at 10 mM, 2.5 lL
of hexamers (at 1 : 10 dilution), 1.25 lL of Multiscribe and
1 lL of RNase inhibitor in a 50-lL ﬁnal volume. The cycling
program was 25C for 10 min, 48C for 30 min, and 95C
for 5 min. The PCR reaction, adapted from a previously
described protocol, was carried out with the qPCR master-
mix-No Rox (Eurogentec, Angers, France) in a 50-lL volume
on the Stratagene MX3005P QPCR system (Agilent Technol-
ogies) with 10 lL of cDNA, 25 lL of Mastermix, 1 lL of
each primer (10 mM), and 0.4 lL of probe (10 mM) [4].
Primers were identical to those previously described,
whereas the probe was slightly modiﬁed (FAM-CAN-
GGACACCCAAAGTAGTCGGTTCC-TAMRA). The cycling
program was 50C for 2 min, 95C for 10 min, 45 cycles at
95C for 15 s, and 60C for 1 min.
Internal control
Nucleic acid extraction, reverse transcription and rtRT-PCR
were monitored by using a quantitated solution of bacterio-
phage MS2, 10 lL of which was spiked into the 200 lL of
CSF. PCR detection of MS2 bacteriophage was performed
with the same Mastermix kit on the same cycler with the
same cycling program in a 15-lL ﬁnal volume including 3 lL
of cDNA, 7.5 lL of mastermix, 0.3 lL of each primer
(10 mM), and 0.15 lL of probe (10 mM). Primer and probe
sequences are available upon request from the correspond-
ing author. For each sample, validation of the run was per-
formed by comparison with the result obtained for MS2
detection. Brieﬂy, a negative MS2 result or an MS2 Ct value
higher than one standard deviation (as compared with the
mean Ct value observed on the whole PCR plate) indicated
either a technical problem in any of the steps or the pres-
ence of inhibitors in the clinical sample. Such a result was
transmitted to the clinician as ‘inconclusive’ or ‘indetermi-
nate’. A similar approach has been described previously [7].
Results
The distribution of age and sex ratio in the population was
49 (1.6), 37 (1.8), 65 (1.8), 49 (0.7), 71 (1.1) and 39 (1.3) for
the following age categories: <1 year, 1–4 years, 5–14 years,
15–24 years, 25–49 years, and >50 years (Table 1).
A total of 310 CSF samples were prospectively processed
in POC laboratories: 85 were positive, 174 were negative,
and 51 were ‘indeterminate’. The same numbers of samples
were received and processed for adults (n = 159) and for
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children (n = 151). However, the large majority of positive
results were observed in children (n = 61, 40.4%) and young
adults (n = 14, 28%) vs. patients older than 25 years (n = 10,
9.2%). There was a signiﬁcant over-representation of children
in the series (p <0.0001, chi-square with Yates correction).
There wass no difference in terms of gender. The rtRT-PCR
gave 81 positive, 225 negative and four ‘indeterminate’
results. A total of 253 of 310 (81.6%) results were concor-
dant with the two tests: they included 81 positive and 172
negative samples (Tables 1 and 2). This test is evaluated with
the QCMD Enterovirus & Parechovirus RNA EQA Pro-
gramme each year. With the rtRT-PCR test as the reference
standard, the performances of the Xpert EV kit on the
GeneXpert system were calculated to be 100%, 98.9%,
97.6%, 100% for Sensibility, Speciﬁcity, positive predictive
value (PPV) and negative predictive value, respectively, for
conclusive results; ‘indeterminate’ results were excluded
from the analysis, as they were considered to be non-conclu-
sive, and corresponding results were sent back as indetermi-
nate to the prescribing clinician; it was mentioned that
another technique would be used on the next day to resolve
the indeterminate status. Interestingly, of the 51 ‘indetermi-
nate’ POC results, two were ultimately revealed to be posi-
tive, which is statistically different from the expected
distribution (p <0.0008, chi-square with Yates correction).
CSFs exhibiting an indeterminate status were not diluted in
POC laboratories. They were tested by use of the second
test within 24 h. If both tests resulted in an indeterminate
status, the CSF was diluted 1 : 10 with sterile phosphate-buf-
fered saline: in this case, only the positive results were ren-
dered, the negative ones being rendered indeterminate, as a
1 : 10 dilution might result in a false-negative result. Con-
cerning the cellularity (red cells and white cells, indepen-
dently), there was no signiﬁcant difference between samples
with indeterminate status and the validated ones (positive or
negative). CSF specimens were received and processed in
POC laboratories throughout the study period. The majority
of positive results were obtained between May and Septem-
ber, with a peak being observed in July.
The mean duration of hospital stay for these patients was
0.8 ± 1.3 days (data not shown). In 2005 (no POC detection
of EV RNA at this time, but EV RNA detection routinely
performed with the same technical protocol on the same
technical equipment), the mean duration of hospital stay was
2.2 ± 1.8 days [3].
Discussion
In Marseille, the recent reorganization of the health structure
(four public hospitals) resulted in a unique core laboratory
for all activities relevant to clinical microbiology, including
virology [5]. Because of the problems of sample transporta-
tion linked to the spatial distribution of the four hospitals,
and to reduce the time needed to provide clinicians with
laboratory documentation, we decided to build two POC
laboratories located in the vicinity of the emergency wards.
Open 24 h everyday and operated by one person (an intern
in biology), each POC laboratory can rapidly perform a large
panel of analyses (24 techniques at present) using various
techniques, such as antigen immunochromatographic detec-
tion and molecular assays based on real-time PCR or RT-
PCR, such as for the detection of EV RNA [5].
In this study, the Xpert EV kit on the GeneXpert system
was evaluated prospectively in real-life conditions. In contrast
to studies performed in laboratories and addressing only the
technical performance, this study took into consideration
parameters such as: (i) sample transportation from the clinical




Xpert EV kit on the GeneXpert system Real time RT-PCR
Positive Negative Indeterminate Positive Negative Indeterminate
<1 49 1.6 14 31 4 13 36 0
1–4 37 1.8 9 24 4 8 29 0
5–14 65 1.8 40 16 9 36 27 2
15–24 49 0.7 13 29 7 14 34 1
25–49 71 1.1 9 48 14 10 60 1
>50 39 1.3 0 26 13 0 39 0
Total 310 – 85 174 51 81 225 4
TABLE 2. Global comparison of results obtained with the
two techniques




Negative Negative 172 55.5
Positive Positive 81 26.1
Negative Positive 0 0
Positive Negative 2 0.65
Negative Indeterminate 2 0.65
Positive Indeterminate 2 0.65
Indeterminate Negative 49 15.8
Indeterminate Positive 2 0.65
Total 310 100
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ward to the POC laboratory; (ii) variations in the ﬂow of
specimens sent to the POC laboratory; (iii) management of a
variety of assays simultaneously by the person on duty; and
(iv) the problems linked to a laboratory operated by almost
40 different interns (most of whom were inexperienced
when starting their 6-month training, and were speciﬁcally
trained to operate POC laboratories) throughout the study
period. Therefore, the results obtained with the Xpert EV
kit depended on other parameters than those (mostly tech-
nical) that are usually addressed by laboratory evaluation.
The results used for comparative analysis with those
obtained with the reference assay used in the core labora-
tory on the molecular virology diagnostics platform [5] were
those recorded in the biological validation network system
of the hospital. There are major points concerning these
results: (i) the PPV of the POC-operated-Xpert EV kit was
excellent (97.6%); (ii) the 16% ‘indeterminate’ results were
of the same order of magnitude as results reported previ-
ously [8]; and (iii) these 16% indeterminate results were not
included in the calculation of Sensibility, Speciﬁcity, PPV, and
negative predictive value, because our goal was not to evalu-
ate the intrinsic technical value of the Xpert EV kit, but
rather to produce an estimate of its value in a real-life POC
strategy for EV RNA detection. In these conditions, POC-
‘indeterminate’ results (not validated) were not considered
to be useful for clinicians, and were therefore not transmit-
ted as results. This point must be underlined, as ‘unvalidated’
results will increasingly appear with the development of
POC tests; indeed, the major performance criterion of a
POC test is high speciﬁcity, thus generating the minimal
number of false-negative results. As previously stated, the
value of a POC test is in ‘ruling in’, rather than ‘ruling out’
[9]. In this 9-month study, a total of 259 results validated at
the POC level were transmitted to the clinician within <4 h. In
these 259 cases, patient management may have been modiﬁed
in terms of antibiotherapy or hospitalization duration, as previ-
ously demonstrated [3]. The hospitalization duration was cal-
culated for patients with a positive EV PCR result. In 2005, we
were using the same EV routine PCR test, and patient manage-
ment was not drastically different. However, these data must
be interpreted with caution, as there are many other factors
that might have contributed to the reduction in hospital dura-
tion. Studies speciﬁcally designed to investigate the cost-effec-
tiveness of a POC-based strategy are required.
For our hospitals, the POC strategy is organized according
to a syndromic approach. Therefore, all CSFs (from patients
with meningitis) received at POC laboratories are tested sys-
tematically for Streptococcus pneumoniae, Neisseria meningitidis,
herpes simplex viruses 1 and 2, and enterovirus. The fact
that POC laboratories are operated by a large number of
people has also played a role in the decision to adopt a
‘rigid’ strategy. However, clinicians who do not wish to use
this system can send CSF specimens directly to the core lab-
oratory with speciﬁc prescriptions. Of course, alternative
protocols adapted to speciﬁc local procedures can be set up
in other laboratories. The cost efﬁcacy of the strategy
proposed here would beneﬁt from a thorough evaluation.
Indeed, as the cost of the GeneXpert assay is far from negli-
gible, it might be pertinent to propose its use only during
the epidemic period of enteroviruses, and to target children
and young adults.
The present study demonstrates that the dual approach
presented here for the diagnosis of EV in CSF has proved efﬁ-
cient, and may be established for pathogens other than EV,
for which rapid diagnosis may signiﬁcantly impact on patient
management, therapeutic attitude, and hospitalization costs.
As the PPV of the Xpert EV kit in POC settings is excel-
lent, validated results do not need conﬁrmation; this may
help to signiﬁcantly reduce the workload generated by EV
RNA testing in the core virology laboratory.
To date, most POC tests have been based on antigen
detection, the sensitivity of which usually varies between
40% and 70% [10–12]. Interestingly, the Xpert EV kit on the
GeneXpert system is based on rtRT-PCR technology, which
provides the advantage of high sensitivity combined with
excellent speciﬁcity. In contrast to antigen detection-based
POC tests, real-time PCR results do not require further
conﬁrmation in the core laboratory. Real-time PCR detec-
tion is therefore suitable for a POC diagnostic strategy, and
merits consideration for other microorganisms for which
detection in a matter of hours may be beneﬁcial for patient
management.
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